Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch
repair deficient endometrial cancer that has come back (recurrent). Deoxyribonucleic acid
(DNA) mismatch repair (MMR) is a system for recognizing and repairing DNA errors and damage.
Mismatch repair deficient tumors (dMMR) may have difficulty repairing DNA mutations during
replication that may affect tumor's response to therapy. Immunotherapy with monoclonal
antibodies, such as tislelizumab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread. Giving tislelizumab may
help treat patients with mismatch repair deficient endometrial cancer.